Semaglutide in Comorbid Schizophrenia Spectrum Disorder and Obesity

NCT05333003 · Active, not recruiting

Last updated 2026-05-28

This clinical trial is testing whether the medication semaglutide can help reduce weight in adults with schizophrenia spectrum disorders and obesity.

Status Active, not recruiting Ongoing, but no longer enrolling new participants.

Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).

Type Interventional (clinical trial)

Design Randomized, single-blind treatment study

Participants 92 people Planned (estimated).

Who can join Ages 18–70 · all sexes

Timeline Started 2022-05 · est. completion 2026-08

Where 1 site · Canada

What this study is testing ClinicalTrials.gov NCT05333003 ↗

Description as written by the study sponsor.

Rates of obesity in patients with schizophrenia-spectrum disorder (SSD)s have reached epidemic proportions, with established contributing effects of antipsychotic (AP) medications. Among agents approved for chronic weight management, glucagon-like peptide-1 receptor agonists (GLP-1RA) are associated with reductions in cardiovascular mortality, with recent FDA approval for once weekly semaglutide for this indication. This study will investigate whether semaglutide is effective in reducing body weight in overweight or obese individuals with SSDs who are on APs and do not demonstrate adequate weight loss on metformin (the first line treatment for weight loss in SSDs).

Treatments tested

Semaglutide Drug

The semaglutide dose will start with 0.25 mg/week, and slowly increased every four weeks as tolerated up to a maximal dose of 2 mg/week
Placebo Other

Placebo will be provided to participants

Main thing measured	Weight change
Sponsor	Centre for Addiction and Mental Health
Conditions studied	Schizophrenia Spectrum Disorders
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05333003 ↗